Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty

NCT01358669 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Revision Surgery of Total Hip Arthroplasty

Interventions

DRUG: Denosumab
OTHER: Placebo

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Collaborators

[object Object]
[object Object]